About us
Developing Next generation Resorbable Embolics
Instylla, Inc. is a privately held company based in Bedford, MA, focused on developing novel resorbable embolic agents to advance interventional radiology, with initial clinical applications in interventional oncology. Instylla was founded in 2017 by Incept LLC and is funded by several leading venture capital groups.
The company’s flagship product, Embrace™ Hydrogel Embolic System, is FDA-approved for hypervascular tumor embolization and offers controlled, targeted, and persistent embolization.

Restoring life, hope, and joy to the world’s sickest patients by materializing novel embolization solutions to improve outcomes.
Our Team
Amarpreet Sawhney, Ph.D.
FOUNDER AND CHAIRMAN
INSTYLLA, INC.
Sean Boyle, MBA
CEO
INSTYLLA, INC.
Fred Khosravi, M.S.
CHAIRMAN AND CEO
IMPERATIVE CARE
Tasneem Dohadwala, M.S., MBA
FOUNDING PARTNER
EXCELESTAR VENTURES
Sean J. Cheng, PhD
MANAGING DIRECTOR
ASCENSION VENTURES
Darshana Zaveri, M.S., MBA
FOUNDER AND
MANAGING PARTNER
CATALYST HEALTH VENTURES
Henry Chen, M.S., J.D.
FOUNDING AND MANAGING PARTNER
DELOS CAPITAL
Daniel Davis, A.B.
CHIEF STRATEGY OFFICER
IMPERATIVE CARE
Karen T. Brown
WEILL CORNELL/
NEW YORK HOSPITAL
Thomas DiBartholomeo
YALE –
NEW HAVEN HOSPITAL
Eric Gandras
NORTH SHORE
UNIVERSITY HOSPITAL
Ripal Gandhi
MIAMI CARDIAC
& VASCULAR INSTITUTE
Suvranu Ganguli
BOSTON
MEDICAL CENTER
Jafar Golzarian
NORTH STAR VASCULAR AND INTERVENTIONAL
Michael Soulen
UNIVERSITY
OF PENNSYLVANIA
Joshua Weintraub
COLUMBIA
PRESBYTERIAN HOSPITAL